Get the Stockscreener App
6.57
0.90%
-0.06
Satellos Bioscience Inc stock is traded at $6.57, with a volume of 67,025.
It is down -0.90% in the last 24 hours and down -29.81% over the past month.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
See More
Previous Close:
$6.63
Open:
$6.68
24h Volume:
67,025
Relative Volume:
1.09
Market Cap:
$139.39M
Revenue:
Net Income/Loss:
$-28.50M
P/E Ratio:
-3.6242
EPS:
-1.8128
Net Cash Flow:
$-25.87M
1W Performance:
-10.55%
1M Performance:
-29.81%
6M Performance:
-10.12%
1Y Performance:
+0.00%
1-Day Range:
$6.515
$7.06
1-Week Range:
$6.51
$7.74
52-Week Range:
$5.44
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Name
Satellos Bioscience Inc
Sector
Industry
Phone
-
Address
-
Compare MSLE vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
6.57 | 139.39M | 0 | -28.50M | -25.87M | -1.8128 |
VRTX
Vertex Pharmaceuticals Inc
|
508.43 | 128.87B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.56 | 94.84B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.54 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.87 | 53.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-26 | Initiated | Guggenheim | Buy |
| Apr-06-26 | Initiated | Leerink Partners | Outperform |
| Mar-11-26 | Initiated | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Stock (MSLE) Latest News
Satellos Bioscience Inc. - Baystreet.ca
Satellos Bioscience (TSX:MSCL) Stock Forecast & Analyst Predictions - Simply Wall Street
Satellos Bioscience Inc. (MSCL.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Satellos Bioscience Inc. - Baystreet.ca
Satellos Bioscience Inc. Common Stock (NASDAQ: MSLE) Stock Price, News & Analysis - kalkine.ca
Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated "Moderate Buy" by Wall Street Brokerages - MarketBeat
Stocks In Play - baystreet.ca
Satellos Bioscience Inc. - Baystreet.ca
Satellos Bioscience Inc. - Baystreet.ca
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - GlobeNewswire Inc.
A form of muscular dystrophy affects an estimated 800,000 people. A drug study is planned for late 2026. - Stock Titan
What's Going On With Satellos Bioscience Inc. Stock Friday? - Wealth Awesome
Why Satellos Bioscience Inc. stock surged yesterday - Wealth Awesome
Satellos Bioscience (TSX:MSCL) Gains Momentum as Clinical Progress and Regenerative Medicine Potential Drive Investor Optimism - kalkine.ca
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 - Investing News Network
Satellos at Cantor healthcare conference: pipeline nears key data - Investing.com
Satellos at Cantor healthcare conference: pipeline nears key data By Investing.com - Investing.com UK
MSCL: Phase II trials of forazapadin show early promise in muscle regeneration, with pivotal data expected soon - TradingView
Satellos Bioscience is facing clinical execution risks—can it regain investor confidence and turn sentiment around? - kalkine.ca
Satellos assigns INN forazapadin to DMD drug candidate - Investing.com
Satellos Bioscience Secures INN ‘Forazapadin’ for Lead Duchenne Drug as Phase 2 Programs Advance - TipRanks
Satellos assigns INN forazapadin to DMD drug candidate By Investing.com - Investing.com Canada
New muscle disease pill from Satellos Bioscience (MSLE) nears key Duchenne trial readout - Stock Titan
A muscle disease treatment candidate gets a new global name: forazapadin - Stock Titan
Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Did Satellos Bioscience (TSX:MSCL) Surge 7.43% on 31 August 2026? - kalkine.ca
Why Satellos Bioscience Inc. stock surged yesterday - Wealth Awesome
Satellos Bioscience to Showcase DMD Drug Program at September Investor Conferences - TipRanks
Satellos to Participate in Upcoming Investor Conferences - The Manila Times
Satellos cash runway through 2027, Phase 2 DMD | MSLE SEC FilingForm 6-K - Stock Titan
Satellos to Participate in Upcoming Investor Conferences - Stock Titan
Satellos Bioscience (TSX:MSCL) Rises 7.43% as Duchenne Clinical Progress and Upcoming Data Catalysts Lift Investor Optimism - kalkine.ca
Satellos Bioscience Stock Falls 7.42% as Clinical-Stage Risk and Development Uncertainty Pressure Sentiment - kalkine.ca
Satellos Bioscience Inc. (TSX:MSCL) Falls 7.42% as Biotech Volatility and Clinical Development Risks Pressure Investor Confidence - kalkine.ca
LifeSci Capital Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Satellos Bioscience (MSLE) Slides Nearly 10% in High-Volume Biotech SelloffCalendar Spread Trade - vinanet.vn
Satellos Bioscience (MSLE) Slides Nearly 10% in High-Volume Biotech SelloffTrend Reversal Picks - dars.gov.et
Empery Asset Management LP Sells 123,000 Shares of Satellos Bioscience Inc. $MSLE - marketbeat.com
LifeSci Capital Initiates Satellos Bioscience(MSLE.US) With Buy Rating, Announces Target Price $22 - Moomoo
Satellos Bioscience Stock Under Pressure as Biotech Volatility Raises Correction Risk - kalkine.ca
Satellos (MSLE) Stock: Ends Higher by 0.59% at $10.15 on the Day; Current Setup: the Session Ends Within the Reported Technical Boundaries in the Latest ReadingMonthly Profile - vinanet.vn
DMD Biotech Delivers Early Muscle Data as SAT-3247 Advances - Streetwise Reports
DMD Biotech Delivers Early Muscle Data as SAT-3247 Advances - Streetwise Reports
Why Satellos Bioscience Inc. stock is gaining today - wealthawesome.com
Satellos Bioscience Stock Drops 3.39% as Investors Weigh Duchenne Muscular Dystrophy Therapy, Clinical Development and Biotech Risk - kalkine.ca
Why Satellos Bioscience Inc. stock fell yesterday - Wealth Awesome
HC Wainwright Reaffirms Buy Rating for Satellos Bioscience (NASDAQ:MSLE) - MarketBeat
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Satellos Bioscience Inc. MSCL Earnings Miss Estimates by 37.0% - Wealth Awesome
Satellos TRAILHEAD Data Suggests Muscle Regeneration as Company Cash Reaches US$61.8M - Streetwise Reports
Satellos Bioscience Inc Stock (MSLE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):